Analysis of clinical trials shows pipeline for therapeutics is small; 99.6 percent of drug attempts fail
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, “Alzheimer’s Disease Drug Development Pipeline: Few Candidates, Frequent Failures,” was published today in the journal Alzheimer’s Research & Therapy.
A comprehensive look at all clinical trials underway shows:
- There are relatively few drugs in development for Alzheimer’s disease.
- The failure rate for AD drug development is 99.6 percent for the decade 2002-2012.
- The number of drugs has been declining since 2009.
“Our goal was to examine historical trends to help understand why Alzheimer’s disease treatment development efforts so often fail,” said Jeffrey L. Cummings, M.D., ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. “With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer’s disease drug development ecosystem needs more support given the magnitude of the problem.”
Read more . . .
The Latest on: Alzheimer’s drug development
[google_news title=”” keyword=”Alzheimer’s drug development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s drug development
- Opinion: Utahns with dementia — and their caregivers — deserve our supporton November 25, 2023 at 5:00 am
All aging isn’t created equal,” writes Kara Dassel, Ph.D. “For the more than 34,000 people in Utah currently living with Alzheimer’s disease and their 99,000 unpaid caregivers, aging takes a very ...
- Dementia patients may be denied NHS drugs as report does not ‘factor in’ burden on familieson November 24, 2023 at 12:00 pm
Dementia patients may be denied life-changing drugs by the NHS after a report concluded that the disease’s burden on families need not be factored in.
- Scientists Find Brain Cholesterol Link to Alzheimer's-Like Damageon November 22, 2023 at 8:00 am
A drug that reduces cholesterol levels in brain cells may reduce neurodegeneration caused by Alzheimer's-associated proteins.
- AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Researchon November 21, 2023 at 8:16 pm
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency.
- New Drug Shows Promise in Treating Alzheimer’s Diseaseon November 21, 2023 at 4:00 pm
Amyloid beta is a protein that is thought to play a role in the development of Alzheimer’s disease. In a clinical trial, lecanemab was shown to slow the decline in cognitive function in patients with ...
- The Tedious Efforts Towards an Alzheimer’s Therapyon November 21, 2023 at 6:33 am
Basic and clinical research as well as efforts of the pharmaceutical industry were successful in providing measures against many health-threatening chronic conditions such as high cholesterol levels, ...
- New Alzheimer’s drug starts first clinical trialon November 21, 2023 at 3:00 am
P roMIS Neurosciences has dosed the first subjects in a Phase Ia clinical trial of PMN310 as a potential Alzheimer’s disease (AD) treatment. PMN310 is a new monoclonal antibody that selectively ...
- The Tedious Efforts Towards an Alzheimer’s Therapyon November 20, 2023 at 4:00 pm
This post is part 3 of a series. Parts 1 can be found here and part 2 can be found here. We have medications for many chronic human diseases on hand. Basic and clinical research as well as efforts ...
- New blood tests for dementia announced, but what can they tell us and who will benefit?on November 17, 2023 at 9:18 am
A five-year, £5 million initiative has just been launched to investigate the feasibility of using new blood tests in the diagnosis of Alzheimer’s disease. Alzheimer’s Research UK and the Alzheimer’s ...
- CT-1812 by Cognition Therapeutics for Alzheimer’s Disease: Likelihood of Approvalon November 16, 2023 at 8:21 pm
CT-1812 is under clinical development by Cognition Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase ...
via Bing News
